6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer: A systematic review and meta-analysis

BACKGROUND: Adjuvant trastuzumab improves survival outcomes of human epidermal receptor 2 positive early breast cancer patients. Currently, administration of 12 months adjuvant trastuzumab is the standard therapy. However, whether 6 months treatment is non-inferior to the standard 12 months treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Xiao, Bo-Ya, Fan, Ji-Quan, Lin, Guo-He, Wang, Chang, Liu, Quentin, Zhao, Yan-Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969267/
https://www.ncbi.nlm.nih.gov/pubmed/33725875
http://dx.doi.org/10.1097/MD.0000000000024995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969267/
https://www.ncbi.nlm.nih.gov/pubmed/33725875
http://dx.doi.org/10.1097/MD.0000000000024995

Ejemplares similares